NASDAQ: CTXRCitius Pharmaceuticals Inc Stock
$0.49-0.04 (-7.55%)
Updated Nov 10, 2026
CTXR Price
$0.49
Fair Value Price
$0.22
Market Cap
$13.53M
52 Week Low
$0.37
52 Week High
$1.54
P/E
-0.28x
P/B
0.2x
P/S
2.23x
PEG
N/A
Dividend Yield
N/A
Revenue
$7.11M
Earnings
-$46.27M
Gross Margin
77.3%
Operating Margin
-641.34%
Profit Margin
-651.3%
Debt to Equity
1
Operating Cash Flow
-$35M
Beta
1.12
Next Earnings
Dec 22, 2026
Ex-Dividend
N/A
Next Dividend
N/A
CTXR Overview
Citius Pharmaceuticals, Inc. operates as a specialized pharmaceutical firm concentrating on the development and market introduction of critical care products. Its efforts are particularly directed towards anti-infective treatments supporting cancer care, various prescription medications, and pioneering mesenchymal stem cell therapies. Mino-Wrap: A novel liquifying gel-based wrap aimed at minimizing infections associated with tissue expanders following breast reconstructive procedures. Halo-Lido: A topical formulation that blends a corticosteroid with lidocaine, intended to deliver both anti-inflammatory and numbing relief to individuals suffering from hemorrhoids. NoveCite: A mesenchymal stem cell therapy currently under development for treating acute respiratory distress syndrome (ARDS). I/ONTAK: An engineered fusion protein, combining IL-2 and diphtheria toxin, purposed for the treatment of patients experiencing persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CTXR's potential to beat the market
- CTXR doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
CTXR
RankedUnranked of 450
RankedUnranked of 450
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $15.83 | A | |
| $916.06 | A | |
| $424.00 | A |
Be the first to know about important CTXR news, forecast changes, insider trades & much more!
CTXR News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CTXR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CTXR ($0.49) is overvalued by 123.66% relative to our estimate of its Fair Value price of $0.22 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
CTXR ($0.49) is not significantly undervalued (123.66%) relative to our estimate of its Fair Value price of $0.22 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
CTXR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CTXR due diligence checks available for Premium users.
Valuation
CTXR fair value
Fair Value of CTXR stock based on Discounted Cash Flow (DCF)
Price
$0.49
Fair Value
$0.22
Overvalued by
122.30%
CTXR ($0.49) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CTXR ($0.49) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CTXR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
CTXR price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.28x
Industry
17.34x
Market
41.12x
CTXR price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.2x
Industry
5.28x
CTXR is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CTXR's financial health
Profit margin
Revenue
$1.5M
Net Income
-$8.9M
Profit Margin
-593.3%
CTXR's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
CTXR's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$142.3M
Liabilities
$66.3M
Debt to equity
1
CTXR's short-term liabilities ($51.65M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CTXR's short-term assets ($43.33M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CTXR's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
CTXR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$8.7M
Investing
-$2.0M
Financing
$23.1M
CTXR's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CTXR vs Biotech Stocks
Citius Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.